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A B S T R A C T   
Purpose: To evaluate the initial results of predicting lymph node metastasis in rectal cancer patients detected in- 
vivo with USPIO-enhanced MRI at 3 T compared on a node-to-node basis with histopathology. 
Methods: Ten rectal cancer patients of all clinical stages were prospectively included for an in-vivo 0.85 mm3 
isotropic 3D MRI after infusion of Ferumoxtran-10. The surgical specimens were examined ex-vivo with an 
0.29 mm3 isotropic MRI examination. Two radiologists evaluated in-vivo MR images with a classification scheme 
to predict lymph node status. Ex-vivo MRI was used for MR-guided pathology and served as a key link between in- 
vivo MRI and final histopathology for the node-to-node analysis. 
Results: 138 lymph nodes were detected by reader 1 and 255 by reader 2 (p = 0.005) on in-vivo MRI with a 
median size of 2.6 and 2.4 mm, respectively. Lymph nodes were classified with substantial inter-reader agree-
ment (κ = 0.73). Node-to-node comparison was possible for 55 lymph nodes (median size 3.2 mm; range 
1.2–12.3), of which 6 were metastatic on pathology. Low true-positive rates (3/26, 11 % for both readers) and 
high true negative rates were achieved (14/17, 82 %; 19/22, 86 %). Pathological re-evaluations of 20 lymph 
nodes with high signal intensity on USPIO-enhanced MRI without lymph node metastases (false positives) did not 
reveal tumor metastasis but showed benign lymph node tissue with reactive follicles. 
Conclusions: High resolution MRI visualizes a large number of mesorectal lymph nodes. USPIO-enhanced MRI 
was not accurate for characterizing small benign versus small tumoral lymph nodes in rectal cancer patients. 
Suspicious nodes on in-vivo MRI occur as inflammatory as well as metastatic nodes.   
1. Introduction 
The presence of lymph node metastases in rectal cancer is a key 
factor in determining prognosis and treatment [1]. Diagnostic lymph 
node staging, however, is still a major challenge [2–4]. Over the past 
decade multiple imaging approaches have been assessed as a biomarker 
to differentiate between benign and malignant lymph nodes [5–10]. The 
size and shape of a lymph node as sole criteria are unreliable measures to 
predict lymph status, since metastatic lymph nodes in rectal cancer are 
often smaller than 5 mm [11,12]. Moreover, variation in interpreting 
MR images leads to predominantly upstaging with potential effects on 
treatment [4,13]. Therefore, there is a need for a more accurate pre-
diction of the presence of lymph node metastases. 
Ferumoxtran-10, consisting of ultrasmall superparamagnetic iron 
oxide (USPIO) particles that become lymphotropic after intravenous 
administration, has previously proven to be a valuable MRI-contrast 
Abbreviations: USPIO, ultrasmall superparamagnetic iron oxide; 2D, 2-dimensional; 3D, 3-dimensional; TME, total mesorectal excision; nCRT, neoadjuvant 
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agent for detecting lymph node metastases [14–16]. Promising clinical 
results for USPIO-enhanced MRI were shown with a pooled sensitivity of 
90 % and specificity of 96 % for multiple solid tumors [17]. 
USPIO-enhanced MRI also showed reproducible results in differentiating 
lymph node metastases in rectal cancer patients [18–20]. These studies 
were performed in clinical trials during the phase of clinical develop-
ment of the product. However, high accuracy was described by detecting 
relatively large lymph nodes which have a higher probability of 
harboring metastases. Moreover, most studies were performed on 1.5 T 
MR systems with 2-dimensional (2D) multi-slice acquisitions, with 
known restrictions in resolution. It was demonstrated that especially the 
diagnostic accuracy for the detection of small lymph node metastases 
(<5 mm) dropped substantially [21]. By using 3-dimensional (3D) 
USPIO-enhanced MRI on a 3 T MR system, it is possible to increase the 
spatial resolution to small isotropic voxels, thereby potentially 
increasing the sensitivity for the detection of small (<5 mm) suspicious 
lymph nodes [22]. Identifying small lymph nodes that are suspicious for 
tumor metastases prior to surgery will contribute in planning for 
adequate treatment. However, whether the smallest lymph nodes that 
retain MR signal intensity after administration of USPIO nanoparticles 
indeed contain metastases requires a meticulous node-to-node valida-
tion. To provide more insight in the potential accuracy of predicting 
small lymph node metastases by using 3D USPIO-enhanced MRI, in-vivo 
detected suspicious lymph nodes have to be evaluated up to final his-
topathological analysis of the identical nodes after resection. 
Therefore, in this study, we aim to present the initial results of the 
histopathological node-to-node validation of lymph nodes that are 
detected in-vivo with sub-mm resolution on 3D USPIO-enhanced MRI at 
3 T in rectal cancer patients. 
2. Material and methods 
The authors had full control of the data and information submitted 
for publication. The study was approved by the institutional review 
boards of the two participating hospitals (NL51335.091.14 & 
NL58295.091.16) and written informed consents were obtained from all 
patients. The study was registered in clinicaltrials.gov (NCT02751606). 
Ferumoxtran-10 (SPL Medical B.V., Nijmegen, The Netherlands) is an 
USPIO contrast agent currently undergoing a multicenter registration 
study in Germany, Switzerland and the Netherlands. The contrast agent 
is currently not commercially available. 
2.1. Patient selection 
In a prospective, two center, diagnostic cohort study in the period 
March 2017 to January 2018 patients from two referral centers with 
biopsy-proven rectal cancer were included. According to clinical endo-
scopic findings, rectal tumors were located within 15 cm from the 
anorectal junction. All patients had to undergo a surgical resection ac-
cording to the principle of a total mesorectal excision (TME) [23]. In 
case of locally advanced rectal cancer (LARC; cT3-,MRF + or cT4), 
neoadjuvant chemoradiotherapy (nCRT) was admitted with an 
increased interval to surgery [24]. nCRT consisted of 25 fractions of 2 
Gray combined with capecitabine 825 mg/m2. Five patients underwent 
neoadjuvant treatment. Lymph nodes of (non)irradiated patients were 
compared for radiological and histological differences. The workflow of 
the study and number of patients asked for inclusion are shown in a 
STARD flow-diagram (Supplemental Fig. 1). Exclusion criteria were 
previous allergic reaction to contrast agents, contra-indication for MR 
investigation and the presence of a malignancy other than rectal cancer. 
2.2. USPIO agent infusion and USPIO-enhanced MRI 
The in-vivo USPIO-enhanced MRI was performed within 2 weeks 
prior to surgery. 24− 36 h prior to the examination, patients were slowly 
intravenously infused with the USPIO particles (Ferumoxtran-10, 
2.6 mg/kg body weight diluted in saline). MR imaging was performed at 
3 T (Siemens Magnetom® Prisma, Erlangen, Germany) using a spine coil 
and a phased array body coil. Patients were supine, feet first positioned 
and received antispasmodic medication intramuscularly (1 mL Scopol-
amine Butyl Bromide, Sanofi-aventis Netherlands B.V.) unless a 
contraindication was present. The MR-protocol consisted of a 3D T1- 
weighted volume-interpolated gradient echo sequence (VIBE-DIXON) 
for anatomical imaging and a 3D T2*-weighted multi-gradient echo 
(mGRE) sequence for recognition of uptake of the contrast agent in the 
lymph nodes. From the VIBE-DIXON sequence 4 image sets were 
generated: in-phase, opposed-phase, water-only and fat-only. The in- 
phase images were used for in vivo lymph node selection. Multiple 
mGRE images were condensed into one T2*-weighted computed echo 
time (TE = 12 msec) image for interpretation of the USPIO presence 
within the identified lymph nodes [25]. No non-enhanced MRI exami-
nations were performed. Details of the specific pulse sequences are 
shown in Table 1. 
2.3. Evaluation of the USPIO-enhanced in-vivo MRI scans 
In-vivo images were evaluated separately by two experienced 
abdominal radiologists (JF/R1 10 and PZ/R2 15 years, respectively), of 
whom one had experience with USPIO-enhanced MRI. The readers were 
blinded to clinical data, histology and each other’s findings. All 
discovered lymph nodes and their locations were annotated in different 
datasets for both readers. Information regarding a lymph node that 
could be selected by one reader and not by the other, was not shared. 
Only mesorectal lymph nodes were selected on T1-weighted MR images 
and annotated by both readers, since these nodes could be compared 
with the ex-vivo MRI. Annotation of the detected lymph nodes was done 
using an annotation tool of the software package MeVisLab (MeVis 
Medical Solutions, Fraunhofer MEVIS). Short axis size of the lymph 
nodes was measured in the transverse plane of the "in phase" T1- 
weighted MR images. The appearances of lymph nodes on T2*- 
weighted MR images were classified for suspicion on containing me-
tastases using a modified classification scheme based on nodal signal 
intensity and architecture (Table 2) [26]. In case of discrepancies be-
tween the classification of the readers (high signal intensity type 1–2 
versus attenuated signal intensity type 6–7), they were asked to 
re-evaluate that lymph node resulting in a consensus read. 
2.4. Ex-vivo MRI of the surgical specimen of the rectum 
After surgery, all TME specimens were fixated in 10 % buffered 
formalin for at least 24 h. MR imaging of the fixated specimens was 
Table 1 
Imaging parameters of the 3 and 7 T MRI scan protocol. From the DIXON VIBE 
sequence 4 image sets were generated: in-phase, opposed-phase, water-only and 
fat-only. The in-phase images were used for in vivo lymph node selection.  
3 T MRI protocol    
T1 DIXON VIBE 3D Multi GRE 
Plane 3D 3D 
Repetition time (msec) 5.8 21.0 
Echo time (msec) 1.2, 2.5 3.6 - 17.2 
Matrix 384*384*192 384*384*224 
Flip angle 10 10 
resolution (mm3) 0.85 × 0.85 × 0.85 0.85 × 0.85 × 0.85  
7 T ex vivo MRI protocol    
Lipid excitation GRE Water excitation GRE 
Plane 3D 3D 
Repetition time (msec) 15.0 30 
Echo time (msec) 3.0 6.2 
Matrix 320*320*256 320*320*256 
Flip angle 10 14 
resolution (mm3) 0.29 × 0.29 × 0.29 0.29 × 0.29 × 0.29  
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performed on a horizontal 7 T preclinical MR system (ClinScan, Bruker® 
BioSpin, Ettlingen, Germany). The ex vivo MRI examinations were per-
formed 1–2 weeks after Ferumoxtran-10 infusion, thus were not USPIO- 
enhanced. Ex-vivo images were evaluated by the coordinating physician 
(not one of the radiologists) by annotating lymph nodes located in the 
mesorectum detected on lipid and water selective GRE images [27]. 
Lymph nodes were defined as such in case of a spherical structure visible 
in three dimensions with low signal intensity on lipid and high signal 
intensity on water selective GRE images. When in doubt whether a 
structure could be a lymph node, it was not annotated. Sizes of the 
lymph nodes were measured in the transverse plane on water selective 
GRE images. Surgical specimens were further processed after lymph 
node recognition was completed. The ex-vivo images of the specimens 
were used as a key link between in-vivo MRI and histopathology. 
2.5. Pathological evaluation 
Pathological evaluation was performed by two experienced colo-
rectal cancer pathologists (IN 22 and CW 25 years, respectively), one at 
each including center, according to the method described by Quirke 
et al. [28]. During macroscopical evaluation, TME specimens were 
sliced into 5 mm thick transverse tissue lamina. Each transverse tissue 
slice was evaluated for harboring lymph nodes. The coordinating 
physician together with one of the pathologists used ex-vivo MR data of 
the TME specimen during macroscopical examination as a guidance for 
lymph node harvesting [27]. Whenever a lymph node could not be 
detected in the specimen, but was likely a lymph node on ex-vivo MRI, 
samples of fatty tissue of that section were separately enclosed. Addi-
tionally, immunohistochemical CD68 staining could be performed to 
objectify the presence of macrophages that are responsible for 
macrophage-linked accumulation of USPIO particles [29]. 
2.6. Node-to-node analysis 
All lymph nodes were annotated on in-vivo MRI, ex-vivo MRI and the 
corresponding tissue cassettes. Node-to-node matching was achieved by 
manually matching nodes from in-vivo MRI to ex-vivo MRI, and subse-
quently from ex-vivo MRI to pathology of the corresponding cassette. 
Lymph nodes visible on in-vivo MRI, but could not be matched to ex-vivo 
MRI were not included analysis. This also held for lymph nodes detected 
during pathology, but could not be matched to a lymph node on ex-vivo 
MRI. From this node-to-node analysis and a binary distinction in in-vivo 
MRI nodal scores (type 1–2-3 is positive, type 4− 5-6− 7 is negative) 
true/false positives and negatives could be extracted with histopathol-
ogy as ground truth. 
2.7. Statistical analysis 
The goal of the study was to compare in-vivo detected lymph nodes 
on USPIO-enhanced MRI with histopathology on a node-to-node basis. 
Numbers, largest diameter and percentages of detected lymph nodes 
were measured from all three modalities. Numbers and sizes were dis-
played in histograms (GraphPad Software, Inc). The results of the 
USPIO-enhanced MRI interpretations for both readers were assessed in 
cross tabulations. Inter-reader variability for all in-vivo scored lymph 
nodes was calculated using nodal types documented and by using a 
dichotomous parameter of the nodal types, dividing lymph nodes in two 
cohorts with (1) predominantly high-signal regions (type 1–2-3, no iron 
uptake) and (2) predominantly attenuated signal regions (type 4− 5- 
6− 7, iron uptake). Lymph nodes detected by only one of the radiologists 
were discarded for the inter-reader variability. The agreement of the 
nodal typing of the lymph nodes by the readers was measured by 
calculating the Cohen’s Kappa (κ) value (poor if κ ≤ 0.20, fair if 0.21 ≤ κ 
≤ 0.40, moderate if 0.41 ≤ κ ≤ 0.60, substantial if 0.61 ≤ κ ≤ 0.80, good 
if κ > 0.80). 
Only lymph nodes that could be matched from in-vivo to histopa-
thology were used in the validation analysis, of which the endpoint was 
the diagnostic performance of the USPIO-enhanced MRI. T-tests, χ2 tests 
and Mann Whitney-U tests were used to determine the statistical sig-
nificance of differences for ordinal and categorical variables (IBM SPSS 
Statistics, version 22). A p value of less than 0.05 was considered as 
statistically significant. 
3. Results 
Ten patients were included, of whom 2 female and 8 male patients 
with a mean age of 64 years (SD 7.7). 5 patients were scheduled for TME 
surgery only (staged 4 cT2N0, 1 cT3N0) and 5 patients for nCRT fol-
lowed by TME (staged: 1 cT3N1, MRF+, 2 cT3N2 and 2 cT4N2). Surgery 
consisted of a low anterior resection (5) or abdominoperineal resection 
(5). Pathology revealed moderate to well differentiated adenocarci-
nomas in all patients. The TME specimens were of a mean size of 
21.4 cm (SD 4.0). Ten complete in-vivo and ex-vivo datasets were 
retrieved. An example of in-vivo MRI is given in Fig. 1. No allergic re-
actions to the infusion of ferumoxtran-10 were observed. 
R1 detected a total of 138 lymph nodes with a median size of 2.6 mm 
(range 1.2–12.3). R2 detected 255 lymph nodes with a median size of 
2.4 mm (range 0.9–12.3). Per patient, this was a median number of 13 
(7–24) lymph nodes for R1 and 23 (15–54) lymph nodes for R2. The total 
number of detected lymph nodes per patient differed between the two 
readers (p = 0.005). No peritumoral deposits were described. All nodal 
enhancement types were described of which type 1 (23.9 % and 18.8 %, 
reader 1 and 2) and type 7 (55.8 % and 43.1 %; R1,R2) most frequently. 
An overview of all classified nodes is shown in Table 3. Sixteen lymph 
nodes were scored with large discrepancies by the readers and were re- 
scored as a type 1 (N = 7) and as a type 7 (N = 9). Nodal classification 
for the nodes detected by the two observers was performed with mod-
erate agreement (κ = 0.433), which improved to a substantial agree-
ment with the subdivision nodal type 1–2-3 versus 4− 5-6− 7 
(κ = 0.732). 
On ex-vivo images, 428 lymph nodes within the 10 specimens were 
annotated with a median size of 2.1 mm (range 0.7–8.9). During path-
ological examination, 216 lymph nodes, of which 19 metastatic, were 
discovered with a median size of 2.9 mm (range 0.7–16.9). This means 
that ex-vivo MRI revealed more lymph nodes than that could be 
discovered during pathological examination. One specimen was 
macroscopically evaluated without ex-vivo MR guidance. Size distribu-
tion of all lymph nodes separately detected on all three modalities are 
Table 2 
Nodal types based on their characteristics on USPIO-enhanced MRI, derived 
from the classification scheme published by Harisinghani et al.(25).  
Nodal 
type 
Post Dose Description 
1 No blackening of node or node is hyperintense to 
surrounding tissue; heterogeneous or 
homogeneous achitecture 
2 Node has central high signal with darkening 
along the peripheral rim; heterogeneous 
architecture 
3 Partial darkening whereby more than 50 % of the 
node has area of high signal intensity; 
heterogeneous architecture 
4 Less than 50 % of node has high signal intensity; 
heterogeneous architecture 
5 Node having an overall dark signal other than 
central or hilar area of fat seen on T1 sequence 
6 Node having an overall dark signal with speckles 
of subtles granulairities, homogeneous 
architecture 
7 Node having an overall dark signal intensity; 
homogeneous architecture  
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displayed in Fig. 2A–D. 
After comparing in-vivo with ex-vivo MR datasets, a node-to-node 
match from in-vivo to ex-vivo was possible for 70 lymph nodes. An 
example of correlating a lymph node from in-vivo MRI to ex-vivo MRI to 
final histopathology is given in Fig. 3. MR-guided pathology enabled a 
correlation from ex-vivo MRI to histopathology for 88 of the 216 lymph 
nodes. By combining these matching results, a match from in-vivo MRI to 
final histopathology was possible for a total of 55 lymph nodes, of which 
43 (out of 138) lymph nodes scored by R1 and 49 (out of 255) lymph 
nodes scored by R2, respectively. The median size of the lymph nodes 
with a complete node-to-node match was 3.2 mm (range 1.2–12.3; size 
distribution displayed in Fig. 2E). 
High signal intensity versus predominantly attenuated signal in-
tensity regions was used for a comparison between USPIO-enhanced 
MRI appearance and pathologic diagnosis. For R1 and R2 respectively, 
the following rates were calculated: true positive rate of 11 % and 11 %; 
false positive rate of 89 % and 90 %; true negative rate of 82 % and 86 %; 
false negative rate 18 % and 14 % (Table 4). Sub-analysis comparing 
irradiated versus nonirradiated lymph nodes and lymph nodes harvested 
from low anterior versus abdominoperineal resection revealed no dif-
ferences in false positive rates. Lymph nodes with predominantly high 
signal intensity appeared as lymph node metastases on pathology in a 
minority of the cases (example shown in Fig. 4). Lymph nodes with 
attenuated signal on USPIO-enhanced MRI appeared frequently as 
normal lymph nodes (Fig. 5). 
Twenty lymph nodes with high signal intensity on USPIO-enhanced 
MRI without lymph node metastases on initial histological evaluation 
were analyzed in further detail. Histological slides were reviewed for 
potentially missed tumor cells. Multiple new histological subsections 
were taken to detect metastasis throughout all compartments of the 
lymph nodes. These re-evaluations did not reveal tumor metastasis but 
showed benign lymph node tissue with reactive follicles. Additional 
staining immunohistochemistry with CD68 showed a normal distribu-
tion of macrophages throughout 6 selected lymph nodes (an example 
shown in Fig. 6). Iron deposits could also not be discovered during 
histopathological evaluation. 
4. Discussion 
The current study showed the first results of 3D USPIO-enhanced 
MRI on a 3 T MR-system. It was technically feasible to perform high- 
quality MR images of the mesorectum showing many detectable 
lymph nodes from 1 mm and larger in size. High-resolution 3D MRI 
enhanced with USPIO nanoparticles allowed the detection of small 
lymph nodes in-vivo, which required a renewed validation. The work-
flow with an intermediate ex-vivo MRI scan of a surgical specimen 
enabled a node-to-node validation in only 31 % and 19 % of the lymph 
nodes detected by two independent readers. Variations were seen in the 
number of detected lymph nodes on both in- and ex-vivo MRI and on 
histopathology. With ex-vivo MR imaging as a reference, 16.3 % of the 
lymph nodes could be related to in-vivo MRI and 20.6 % to definite 
histopathology, respectively. 
Since the introduction of the USPIO nanoparticles, studies have 
shown high accuracy for malignant lymph node detection [30]. These 
results could not be reproduced. Where high signal intensity regions on 
iron-sensitive MRI were previously reported as highly predictive for 
tumor metastasis [19], suspicious lymph nodes in our cohort retained 
high MR signal intensity without a pathological substrate. Metastatic 
changes were seen on pathology in only a 6 of our evaluated suspicious 
lymph nodes (type 1–2-3). Apart from 3 lymph nodes that consisted 
predominantly of acellular mucin, most lymph nodes had a preserved, 
non-metastatic architecture with reactive lymph nodal follicles and 
Fig. 1. Example of two lymph nodes detected on the in-vivo 3D T1-weighted DIXON-VIBE images and the 3D T2*-weighted mGRE images 24-36 h after infusion of 
Ferumoxtran-10. Both image sets are displayed in three orientations: a transverse view on A (T1-weighted) and B (T2*-weighted), a coronal view on C (T1-weighted) 
and D (T2*-weighted), and a sagittal view on E (T1-weighted) and F (T2*-weighted). The lymph node encircled in red on all displayed images (A-F) was rated as a 
type 1, ‘high signal intensity’ node. The lymph node encircled in blue on the axial images (A-B) was rated as a type 7, ‘low signal intensity’ node. 
Table 3 
Overview of different nodal types that were scored by the two readers appointed 
to the lymph nodes detected that were detected on in-vivo 3D MRI datasets.   
Nodal type described by reader 1 
Frequency (%) 




33 (24 %) 48 (19 %) 
Type 
2 
2 (1,5%) 39 (15 %) 
Type 
3 
14 (10 %) 6 (3%) 
Type 
4 
10 (7%) 18 (7%) 
Type 
5 
0 (0%) 1 (1%) 
Type 
6 
2 (1,5%) 31 (12 %) 
Type 
7 
77 (56 %) 112 (43 %) 
Total 138 (100 %) 255 (100 %)  
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macrophages present within the lymph nodes. 
The high signal intensity in non-metastatic lymph nodes indicates a 
lack of USPIO-loaded macrophages or insufficient accumulation of iron 
particles in lymph nodes to cause a drop in signal intensity. This may be 
explained by an inflammatory response within these lymph nodes, 
either caused by the presence of the tumor, or as a consequence of nCRT. 
Although sub-analysis comparing irradiated versus nonirradiated lymph 
nodes revealed no differences, this observation might be due to the 
number of included patients. It is conceivable that an increased immune 
response with reactive lymphoid follicles could mimic a higher density 
of cells and limit the accumulation of iron particles. Two studies 
reporting on USPIO appearance in inflammatory lymph nodes described 
both signal reduction as well as reduced USPIO particles in macrophages 
[20,31]. A reduced uptake of USPIO particles in macrophages could 
have led to higher signal intensities within nonmetastatic, inflammatory 
lymph nodes, but this was not investigated in further detail. Histological 
investigation in all dimensions of a subset of lymph nodes could not 
reveal small tumor deposits within the node which could have been an 
explanation for the remaining high signal intensity. The exact cause is of 
these high signal intensity lymph nodes on USPIO-enhanced MRI 
Fig. 2. Size distribution of all detected lymph nodes for the different detection methods. (A) shows the size distribution of the nodes detected by reader 1 on the in- 
vivo MRI dataset; (B) shows the size distribution of the nodes detected by reader 2 on the in-vivo MRI dataset; (C) shows the size distribution of the nodes detected on 
ex-vivo MRI dataset by the trained physician; (D) shows the size distribution of the nodes detected on histopathology; (E) shows the size distribution of the lymph 
nodes that were detected on all modalities and were matched on a node-to-node basis. The nodal size in (E) was measured at histopathology on the microscopical 
tissue slices. 
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without tumor metastasis found on histology remains unclear. 
The standardized classification scheme was used with substantial 
interobserver agreement between the two readers. Mainly lymph nodes 
with either high signal intensity or without signal were described, 
meaning that intermediate nodal appearances were not frequently seen. 
A large discrepancy was seen between the number of lymph nodes 
detected. Differences in numbers of detected mesorectal lymph nodes 
may be reader-dependent based on the experience of the radiologist or 
on the time that was invested in lymph node evaluation [32]. The 
evaluation time for each of the two MRI readers was not measured, but 
the time spent could partly account for the difference. Another reason 
could be the relative inexperience with the MRI sequences used for 
imaging lymph nodes located in the mesorectum. Although the number 
of detected lymph nodes differed, the classification of the nodes by both 
readers was very similar. 
A final node-to-node match was not possible for many nodes detected 
by the readers. Challenges were found in both translations from in-vivo 
to ex-vivo MRI as well as from ex-vivo MRI to pathology. Firstly, due to 
differences in spatial resolution, not all nodes discovered on ex-vivo MRI 
could be discovered in-vivo. Secondly, lymph nodes scored in-vivo were 
located throughout the whole mesorectum and distal mesocolon and 
part of those could have remained in situ after surgery. Thirdly, formalin 
fixation could have interfered with the translation from in-vivo to ex-vivo 
MR, since it can lead to shrinkage and may alter anatomical references 
compared to the in-vivo situation [33,34]. Fourthly, the challenging part 
in linking ex-vivo MRI to pathological examination was the translation 
from 3D to a 2D pathological work-up [27]. 
Previous studies of similar node-to-node comparisons of lymph 
nodes showed better outcomes without using an intermediate MRI scan 
[18,19]. However, spatial resolution of the 1.5 T MRI images was lower, 
and the number of detected lymph nodes per patient was much lower 
(333 nodes in pathology of 28 patients [19], versus 216 nodes in 10 
patients in our study), indicating a bias towards larger nodes. With that 
study design, 62–65 % of the lymph nodes could be matched with a 
mean size diameter of 4.6–4.7 mm compared to our median 
2.4–2.6 mm. In line with other studies, larger lymph nodes could also be 
more successfully linked to pathology. New imaging techniques with 
concomitant higher spatial resolution will visualize smaller structures, 
which will lead to challenges in translating imaging findings to the 
reference standard. Therefore, the size of lymph nodes plays a sub-
stantial role in the success of node-to-node matching. 
A few limitations should be discussed. First, the translation from in- 
vivo to pathology had remaining challenges as described above, which 
led to a selection bias for larger lymph nodes included in the node-to- 
node analysis. Second, the size of the study cohort ideally would have 
been larger with a greater harvest of lymph nodes on imaging as well as 
on pathology. Despite the small number of included patients, a large 
number of lymph nodes could still be examined. Third, our study 
Fig. 3. Example of a lymph node that was seen on all three modalities, matched from in-vivo to ex-vivo MRI to histopathology. A and B show coronal views of one 
partition of 3D in-vivo MRI datasets 24-36 h after infusion of Ferumoxtran-10, of which A is the in-phase image of the VIBE-DIXON dataset and B is the T2*-weighted, 
iron-sensitive image of water content showing a type 1 lymph node. C and D show coronal views of lipid (C) and water (D) excited ex-vivo MRI. That same lymph 
node in the red box was identified in the specimen based on relative position with the rectum, blood vessels and other lymph nodes. E shows definite histopathology 
of the indicated lymph node of a size of 2.9 mm: normal follicular architecture without the presence of tumor metastasis. 
Table 4 
Cross tabulation of the definite pathological diagnosis compared to the lymph nodes with predominately high signal intensity (1,2,3) and attenuated signal intensity 
(4,5,6,7).  









MR classification type 
1,2,3 
3 23 26 MR classification type 
1,2,3 
3 24 27 
MR classification 
type 4,5,6,7 
3 14 17 MR classification type 
4,5,6,7 
3 19 22 
Total 6 37 43 Total 6 43 49  
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contained a limited number of matched lymph nodes that contained 
tumor metastases which might be due to the inclusion of non-locally 
advanced or LARC treated with nCRT. 
To conclude, the current study is the first to present 3-dimensional 
3 T USPIO-enhanced MRI in rectal cancer patients correlated to histo-
pathology. Lymph nodes with high signal intensity on in-vivo MRI were 
either benign with high immunologic activity or contained metastases. 
There are challenges to overcome regarding to improve node-to-node 
matching from clinical MRI to pathology. Further prospective studies 
are needed to provide more insight into the function and behavior of 
lymph nodes in rectal cancer and improvements are to be made to 
correlate smaller lymph nodes to histopathological findings. 
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